Surgical Results and Complications for Open, Laparoscopic, and Robot-assisted Radical Prostatectomy: A Reverse Systematic Review

Tomás Bernardo Costa Moretti¹, Luís Alberto Magna², Leonardo Oliveira Reis³,4,*

¹Doctoral Program in Medical Pathophysiology and UroScience, Division of Urology, Faculty of Medical Sciences, State University of Campinas, Campinas, Brazil; ²Department of Medical Genetics, State University of Campinas, Campinas, Brazil; ³Center for Life Sciences, Pontifical Catholic University of Campinas, Campinas, Brazil

Abstract

Context: The advantages of minimally invasive surgery for radical prostatectomy (RP) have been demonstrated in a number of systematic reviews (SRs). However, the rigorous study selection process for SR means that a lot of information can be excluded, leading to a very specific clinical scenario that is often unrepresentative of real life. Our new reverse SR methodology generates a heterogeneous population database that covers a wide range of clinical scenarios.

Objective: To compare perioperative surgical results and complications for open retropubic RP (RRP), laparoscopic RP (LRP), and robot-assisted RP (RARP) in a reverse SR.

Evidence acquisition: Eight databases were searched for SRs on RRP, LRP, or RARP between 2000 and 2020 (80 SRs). All references used in these SRs were captured for analysis (1724 articles). Perioperative outcomes and complications were compared among the RRP, LRP, and RARP approaches.

Evidence synthesis: We identified 559 (32.4%) reports on RRP, 413 (23.9%) on LRP, and 752 (43.7%) on RARP, involving 1,353,485 patients overall. RARP showed a significantly higher annual volume of surgery per surgeon (AVSS) in comparison to RRP and LRP (mean 64.29, 43.26, and 41.47, respectively), a higher percentage of low-risk patients (prostate-specific antigen <10 ng/ml, Gleason <7, stage <cT2), and a lower rate of lymphadenectomy, culminating in a lower complication rate (12.3% for RARP, 16.3% for LRP, 20.2% for RRP). Among all outcomes, only AVSS was significantly correlated with complication rates. An AVSS of 30, 95 and 95 surgeries/yr was required for RARP, LRP, and RRP, respectively, to obtain a complication rate of 12.3% (average for RARP). RARP showed better performance for all perioperative variables studied except for operative time (operative time: 199.8 vs 214.9 vs 169.5 min; estimated blood loss: 228.2 vs 408.0 vs 852.1 ml; blood transfusion rate: 2.8% vs 6.5% vs 19.8%; length of stay: 2.9 vs 5.7 vs 6.1 d; catheter time: 7.8 vs 8.5 vs 11.0 d for RARP vs LRP vs RRP).

Conclusions: Our reverse SR involved a wide real-life representative sample and reference values established in the literature and revealed that minimally invasive surgery had the best perioperative and complication results, especially RARP.

* Corresponding author. Center for Life Sciences, Pontifical Catholic University of Campinas, R. John Boyd Dunlop s/n, Campinas, São Paulo 13060-904, Brazil. Fax: +55 19 35217481.
E-mail address: reisleo@unicamp.br (L.O. Reis).
1. Introduction

The advantages of minimally invasive surgery in the surgical treatment of prostatic carcinoma are well known and are recognized by the European Association of Urology and American Urological Association guidelines. These advantages include greater performance, which was associated with less complex cases, higher annual surgeon volume, and greater performance.

Patient summary: We used a wide sample representative of real-life surgical practice and reference values established in the literature for three techniques for removal of the prostate to guide patients and physicians in deciding the best surgical treatment for prostate cancer according to availability.

© 2022 The Authors. Published by Elsevier B.V. on behalf of European Association of Urology. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).

2. Evidence acquisition

2.1. Description of the methodology

In classic SR, a systematic search is performed in databases to locate original clinical studies that answered a specific question. After this search, studies that are homogeneous and comparable—that is, studies that used the same methods, populations, and outcomes—are selected for inclusion and can be merged for statistical analysis, called a meta-analysis [6,7].

In the case of RSR, the opposite path is followed. The literature search is carried out with the objective of identifying all SRs in the history of the technique under study, regardless of the question of interest, and gathering as many of these studies as possible to generate a heterogeneous population with complete information for the outcomes that most interested the research community in that area. At this stage, when gathering all the SRs, the main focus is to capture all the studies included in these reviews that were used to answer the investigators’ questions (Supplementary material).

2.2. Search methodology and study design

In December 2020, a literature search was carried out using eight databases: PubMed, Web of Science, Cochrane Library, Embase, ProQuest, CINAHL (The Cumulative Index to Nursing and Allied Health Literature), VHL/Bireme, and Scopus (Fig. 1). We searched for SRs, with or without meta-analysis, that addressed the techniques of RRP, LRP, and RARP, with a general strategy based on health descriptors and synonyms referring to the terms “Laparoscopy”, “Open”, “Retropublic”, “Prostatectomy”, “Robotic Surgical Procedures”, “Systematic Review”, and “Meta-analysis” in the “Title, Abstract and Subject” fields. We then applied the limiters “humans”, gender (“male”), language (“English”), and type of study (“Systematic Review”). The period in the literature was between January 1, 2000 and December 5, 2020. For each database, and adaptation of the search methodology necessary was carried out (Supplementary material).

After the reviews were identified in the initial search, two researchers (T.B.C.M. and L.O.R.) independently selected reviews that included at least one of the three RP techniques. After the initial screening, the full texts were analyzed and any discrepancies were resolved after open discussion between the authors. Reviews without systematization of the search or integrative methodology, conference and congress abstracts, and papers on other techniques were excluded.

Owing to the difficulty in standardizing health descriptors (MeSH terms) for the databases and classifying a study as an SR, we included studies that, despite not mentioning if the PRISMA criteria [4] were followed in their methodology, provided a clear description of the systematization of the search criteria.

Once all the SRs were chosen, the next step was to extract all the articles cited in the bibliographic references that were included in these SRs for analysis. Publications that were abstracts, meeting reports, or congress proceedings were excluded. As before, two researchers separately reviewed the studies (T.B.C.M. and L.O.R.) and discrepancies in selection were resolved via open discussion.

After the sample was chosen via the systematized method described, all the studies were analyzed by the main author (T.B.C.M.) and the largest amount of data available was captured and tabulated in a dedicated Excel spreadsheet.
When a study evaluated more than one cohort, each one was considered as an isolated study and was called a report, which is the unit of publication used in the study. The global content from all of the studies selected, including bibliographic, demographic, and clinicosurgical variables, was used to generate a reference population database for various studies and applications.

### 2.3. Variables analyzed and comparative methods

For this study, perioperative variables separated into the three groups (RRP, LRP, and RARP) were analyzed, including: number of patients, annual volume of surgeries per surgeon (AVSS), age (yr), body mass index (kg/m²), initial prostate-specific antigen (PSA; mg/dl), Gleason score (mean and stratified), clinical T stage, operative time (min), estimated blood loss (EBL; ml), blood transfusion rate (%), length of hospital stay (d), bladder catheterization time (d), and overall and stratified perioperative complication rates (minor, major, and Clavien-Dindo grade I–V [8]).

The mean values for these variables were computed to calculate population reference values. A temporal analysis of the variable means was performed by dividing the reports into four periods in relation to year of publication: first period, before 2005; second period, 2006–2010; third period, 2011–2015; and fourth period, after 2015). In addition, a correlation analysis of the variables was performed to identify factors related to the complication rate.

### 2.4. Statistical analysis

The measure of central tendency was represented by the mean, and dispersion by the standard error of the mean. Comparisons between means were performed using the parametric analysis of variance (ANOVA) test, with multiple variables analyzed according to the homogeneity of the variance, as defined according to the Levene test (Tukey, Bonferroni, or Games-Howell correction). Correlation analyses of continuous variables were performed using Spearman’s correlation. The regression curve was adjusted using the rational regression model (nonlinear). The significance level was set at \( p < 0.05 \) (two-tailed). Statistical analyses were performed in SPSS v.24. Curve Express Professional v2.7 was used for regression graphs and adjustments.

### 3. Results

The first stage of the systematic search for SRs on RP identified 634 studies in eight databases. After excluding 107
In the second stage, comparisons as visualized in Figure 2, Robotic surgery of perioperative variables revealed statistically significant differences between RRP and LRP (Table 1). For PSA <10 ng/ml, Gleason <7, stage cT2 undergoing RARP, techniques, with a higher percentage of low-risk patients, there were significant differences between the RARP group and the other two. For the initial staging variables, there were significant differences between RRP and LRP (Fig. 1).

Descriptive and comparative statistics for preoperative clinical characteristics for the three technique groups are listed in Table 1.

The mean number of patients was significantly higher for the RRP studies (n = 1577) than for the other two techniques. The higher number of patients in a shorter time led to a higher mean AVSS for RARP (64.29) than for RRP (43.26) and LRP (41.47). For the initial staging variables, there were significant differences between the RARP group and the other two techniques, with a higher percentage of low-risk patients (PSA <10 ng/ml, Gleason <7, stage cT2) undergoing RARP, and a similar profile between RRP and LRP (Table 1).

Descriptive and comparative statistics for perioperative variables for the three groups are listed in Table 2. Analysis of perioperative variables revealed statistically significant differences among the three techniques for almost all the comparisons, as visualized in Figure 2.

Robotic surgery showed better performance for all of the variables studied, except for operative time, which was shortest with the open approach.

Temporal analysis revealed that in the first period (before 2005), RRP and LRP were the techniques most used for patients with lower risk (PSA <10 ng/l, Gleason <7, stage T1–2), with better perioperative results obtained with LRP. For the second period there was a change in the case pattern for RARP, with a greater proportion of patients at low risk undergoing surgery via this approach and a gradual improvement in perioperative results over time until the fourth period, when discrepancies become less evident. Regardless of the period, the best perioperative results, except for operative time, were observed for RARP (Table 3).

After simple correlation analysis among the variables studied, only AVSS was significantly correlated with the overall complication rate among the techniques (Table 4).

After nonlinear regression using the rational model, correlations were adjusted to allow prediction of complication rates by AVSS (Table 5). Using this model, AVSS simulation was performed based on the best average AVSS result among the techniques, which was for RARP, with a complication rate of 12.3% for an AVSS of 30.15 surgeries. For RRP, it took 95.33 surgeries/yr per surgeon to achieve a complication rate of 12.3%, and a similar AVSS of 95.41 surgeries/yr for LRP to achieve a complication rate of 12.8% (Fig. 3).

4. Discussion

In the current study we applied a new methodology called RSR to capture evidence in SRs over the 20-yr history.

| Table 1 – Descriptive statistics for clinical variables by surgical technique and univariate comparative analysis of mean values |
| Parameter | A: Open RP | B: Laparoscopic RP | C: Robot-assisted RP | Analysis of variance |
|-----------|------------|------------------|---------------------|---------------------|
| Patients (n) | 559 881 719 | 1577 | 309 | 413 105 760 | 256 | 24 | 752 366 006 | 487 | 122 | <0.001 | AB/AC |
| AVSS | 270 151 656 43.26 3.53 | 266 64 331 41.47 | 2.53 | 504 111 900 | 64.29 | 4.14 | <0.001 | AC/BC |
| Age (yr) | 448 545 521 62.78 0.16 | 381 90 929 62.91 | 0.15 | 664 312 188 | 61.42 | 0.12 | <0.001 | AC/BC |
| BMI (kg/m²) | 121 43 979 26.18 0.17 | 179 39 270 26.32 | 0.14 | 463 111 753 | 27.00 | 0.09 | <0.001 | AC/BC |
| PSA (mg/dl) | 330 157 184 8.91 0.26 | 358 79 110 8.75 | 0.17 | 599 143 034 | 7.71 | 0.19 | <0.001 | AC/BC |
| PSA <4 mg/dl (%) | 50 53 710 17.55 1.27 | 24 7245 16.88 | 1.34 | 34 12 923 | 20.48 | 1.19 | 0.347 | N.S. |
| PSA 4–10 mg/dl (%) | 55 49 56 75.67 1.43 | 31 9764 60.34 | 2.28 | 34 12 923 | 65.69 | 1.18 | 0.02 | AC |
| PSA 10–20 mg/dl (%) | 45 75 686 20.00 1.11 | 33 11 359 | 24.53 | 1.71 | 21 89 774 | 13.96 | 1.70 | <0.001 | AC/BC |
| PSA >20 mg/dl (%) | 27 99 422 8.54 0.97 | 16 8850 14.23 | 4.20 | 12 82 008 | 5.17 | 1.54 | 0.57 | N.S. |
| cGS 7 (%) | 178 143 018 55.92 1.50 | 144 35 040 | 58.39 | 1.59 | 342 175 112 | 53.25 | 1.10 | 0.029 | BC |
| cGS 7 (%) | 165 137 255 43.26 1.25 | 131 33 592 | 33.33 | 1.19 | 322 172 979 | 35.56 | 0.80 | 0.304 | N.S. |
| Stage cT1 (%) | 225 174 785 58.66 1.36 | 211 44 589 | 57.23 | 1.64 | 353 172 436 | 68.76 | 1.01 | <0.001 | AC/BC |
| Stage cT1a (%) | 27 20 924 5.70 2.32 | 28 6274 5.71 | 2.54 | 21 8340 | 6.05 | 0.28 | 0.203 | N.S. |
| Stage cT1b (%) | 28 23 280 7.83 2.86 | 32 7825 7.83 | 2.39 | 22 6974 | 1.11 | 0.28 | 0.192 | N.S. |
| Stage cT1c (%) | 131 90 360 58.63 1.93 | 140 28 402 | 57.30 | 1.94 | 210 45 774 | 71.30 | 1.21 | <0.001 | AC/BC |
| Stage cT2 (%) | 212 165 917 38.70 1.28 | 205 39 521 | 41.16 | 1.39 | 326 161 285 | 31.76 | 1.07 | <0.001 | AC/BC |
| Stage cT2a (%) | 83 77 357 26.22 1.41 | 102 18 037 | 25.41 | 1.11 | 144 34 059 | 19.37 | 0.99 | <0.001 | AC/BC |
| Stage cT2b (%) | 71 70 033 15.94 1.56 | 93 16 936 | 10.83 | 1.09 | 117 29 388 | 8.11 | 0.81 | <0.001 | AB/AC |
| Stage cT2c (%) | 42 34 184 9.57 1.32 | 12 482 10.60 | 1.56 | 62 | 17 403 | 6.07 | 0.96 | 0.073 | N.S. |
| Stage cT3 (%) | 118 110 734 8.04 1.24 | 99 24 971 | 9.67 | 1.14 | 184 142 019 | 5.91 | 0.69 | 0.222 | BC |
| Stage cT3a (%) | 24 13 859 10.38 3.61 | 43 8222 | 11.80 | 1.55 | 42 11 360 | 8.38 | 1.39 | 0.412 | N.S. |
| Stage cT3b (%) | 13 10 393 3.24 1.22 | 23 5466 | 4.52 | 1.01 | 30 9675 | 3.26 | 0.68 | 0.519 | N.S. |
| Stage cT4 (%) | 8 7 836 1.54 0.69 | 4 2689 | 1.13 | 0.76 | 11 7489 | 0.71 | 0.32 | 0.503 | N.S. |

N = number of reports; Np = number of patients; AVSS = annual volume of surgeries per surgeon; BMI = body mass index; PSA = prostate-specific antigen; cGS = clinical Gleason score; RP = radical prostatectomy; SE = standard error of the mean; N.S. = not significant (at two-tailed p > 0.05).

1 Multiple comparison tests among groups A (open RP), B (laparoscopic RP), and C (robot-assisted RP) with appropriate correction: a, Tukey; b, Bonferroni; or c, Games-Howell correction.
Table 2 – Descriptive statistics for perioperative variables by surgical technique and univariate comparative analysis of mean values

| Parameter                          | A: Open RP                      | B: Laparoscopic RP               | C: Robot-assisted RP              | Analysis of variance |
|------------------------------------|---------------------------------|----------------------------------|-----------------------------------|----------------------|
|                                   | \( N_r \) | \( N_p \) | Mean | SE  | \( N_r \) | \( N_p \) | Mean | SE  | \( N_r \) | \( N_p \) | Mean | SE  | \( p \) value | Multiple comparison |
| Operative time (min)              | 179    | 54 876 | 169.53 | 3.89 | 326    | 73 251 | 214.92 | 3.57 | 473    | 110 717 | 199.78 | 3.04 | <0.001 | AB/AC/BC |
| Pelvic lymphadenectomy (%)        | 110    | 78 970 | 82.69  | 2.68 | 162    | 46 893 | 49.30  | 2.17 | 184    | 122 390 | 59.53  | 2.53 | <0.001 | AB/AC/BC |
| Nerve-sparing rate (%)            | 128    | 62 116 | 67.05  | 2.49 | 185    | 43 744 | 56.65  | 1.96 | 240    | 67 212  | 80.57  | 1.24 | <0.001 | AB/AC/BC |
| Unilateral nerve-sparing (%)      | 85     | 40 661 | 26.09  | 2.88 | 158    | 39 108 | 19.96  | 0.98 | 181    | 56 043  | 25.33  | 1.36 | 0.010  | BC |
| Bilateral nerve-sparing (%)       | 103    | 56 266 | 59.52  | 2.90 | 178    | 42 389 | 43.49  | 2.08 | 215    | 61 804  | 62.50  | 1.70 | <0.001 | AB/BC |
| Estimated blood loss (ml)         | 194    | 45 141 | 852.11 | 29.95| 260    | 46 361 | 408.05 | 14.09| 454    | 104 747 | 228.18 | 6.22 | <0.001 | AB/AC/BC |
| Blood transfusion (%)             | 157    | 347 781| 19.77  | 1.49 | 228    | 54 389 | 6.55   | 0.55 | 243    | 143 225 | 2.83   | 0.32 | <0.001 | AB/AC/BC |
| Conversion to open RP (%)         | N.A.   | N.A.   | N.A.   | N.A. | 170    | 42 013 | 1.02   | 0.16 | 128    | 29 975  | 0.90   | 0.18 | 0.795  | N.S. |
| Length of stay (d)                | 159    | 395 351| 6.01   | 0.35 | 227    | 55 730 | 5.73   | 0.22 | 338    | 117 748 | 2.90   | 0.14 | <0.001 | AB/AC/BC |
| Catheter time (d)                 | 90     | 18 007 | 11.03  | 0.51 | 218    | 41 204 | 8.50   | 0.21 | 246    | 54 800  | 7.81   | 0.17 | <0.001 | AB/AC/BC |
| Complication rate (%)             | 148    | 368 848| 20.17  | 1.38 | 243    | 62 387 | 16.33  | 0.76 | 282    | 148 237 | 12.30  | 0.52 | <0.001 | AB/AC/BC |
| Minor complications (%)           | 26     | 10 759 | 20.37  | 3.34 | 109    | 30 049 | 12.70  | 1.10 | 109    | 33 494  | 10.08  | 0.67 | <0.001 | AC |
| Major complications (%)           | 27     | 10 822 | 7.01   | 1.51 | 112    | 30 256 | 5.35   | 0.50 | 105    | 33 407  | 3.54   | 0.35 | 0.002  | BC |
| Clavien I complications (%)       | 13     | 7602   | 8.05   | 1.41 | 46     | 17 318 | 7.38   | 0.94 | 73     | 25 640  | 5.18   | 0.61 | 0.059  | N.S. |
| Clavien II complications (%)      | 13     | 7602   | 17.71  | 5.02 | 48     | 17 989 | 6.33   | 0.72 | 70     | 25 903  | 4.47   | 0.41 | <0.001 | AB/AC |
| Clavien IIIa complications (%)    | 13     | 5211   | 4.49   | 1.48 | 42     | 15 112 | 2.72   | 0.43 | 57     | 21 797  | 2.18   | 0.46 | 0.103  | N.S. |
| Clavien IIIb complications (%)    | 12     | 5128   | 5.03   | 1.72 | 36     | 13 624 | 2.35   | 0.39 | 50     | 18 001  | 1.38   | 0.23 | <0.001 | AB/AC |
| Clavien IVa complications (%)     | 13     | 4943   | 0.96   | 0.60 | 31     | 10 843 | 0.64   | 0.18 | 46     | 18 755  | 0.52   | 0.16 | 0.550  | N.S. |
| Clavien IVb complications (%)     | 9      | 3532   | 0.00   | 0.00 | 21     | 7028   | 0.05   | 0.05 | 35     | 12 912  | 0.02   | 0.01 | 0.550  | N.S. |
| Clavien V complications (%)       | 28     | 208 494| 0.24   | 0.05 | 24     | 8402   | 0.05   | 0.03 | 39     | 30 565  | 0.04   | 0.03 | <0.001 | AB/AC |

\( N_r \) = number of reports; \( N_p \) = number of patients; SE = standard error of the mean; RP = radical prostatectomy; N.S. = not significant (two-tailed \( p > 0.05 \)); N.A. = not applicable.

1. Multiple comparison tests among groups A (open RP), B (laparoscopic RP), and C (robot-assisted RP) with appropriate corrections: a, Tukey; b, Bonferroni; or c, Games-Howell corrections.
of modern RP. Although the current SR methodologies are very effective in filtering the evidence to allow comparison of methodologically similar studies, the need for homogeneity often hinders inferences in relation to daily clinical practice, since the scenarios defined in SRs are often not representative of the real world.

In general, our RSR findings corroborate already established evidence that minimally invasive surgery yields better perioperative results in comparison to open surgery. Except for operative time, RARP had superior results to RRP and LRP in terms of the EBL, blood transfusion rate, hospital stay, urinary catheterization time, and complication rate. LRP had a longer operative time, and intermediate results between RRP and RARP for the other variables described above. These advantages explain in part the significantly higher AVSS for RARP.

One of the largest SRs was presented by Novara et al in 2012 [9] and included 110 studies on RARP, for which there was a mean operative time of 152 min, EBL of 166 ml, a transfusion rate of 2%, length of stay of 1.9 d, catheterization time of 6.3 d, and an overall complication rate of 9% (4% grade I, 3% grade II, 2% grade III, 0.4% grade IV, and 0.02% grade V). The meta-analysis comparing the weighted mean difference (WMD) between RRP and RARP showed better results for RARP regarding blood loss (WMD 582.77, 95% confidence interval [CI] 435.25–730.29; p < 0.001) and the blood transfusion rate (WMD 7.55, 95% CI 3.65–15.64; p < 0.001), but there were no significant differences in operative time (WMD −15.81, 95% CI −68.65 to 37.03; p = 0.56) or complication rate (WMD 1.25, 95% CI 0.53–2.93; p = 0.61). In comparison, we found worse RARP outcomes according to our analysis of 752 reports, with a mean operative time of 119.8 min, EBL of 228.2 ml, transfusion rate of 2.8%, length of stay of 2.9 d, catheterization time of 7.8 d, and a complication rate of 12.3%.

To date, the largest SR comparing intraoperative and perioperative complications among the three PR techniques was performed by Tewari et al [10] in 2012, which included 39 cohorts for RRP, 57 for LRP, and 42 for RARP. The total intraoperative complication rate was significantly higher for RRP (1.5%) versus RARP (0.4%; p < 0.0001) and for LRP (1.6%) versus RARP (0.4%; p < 0.0001). There were also significant differences in the total perioperative complication rate for RARP (7.8%) versus RRP (17.9%; p < 0.0001) and versus LRP (11.1%; p = 0.002). By comparison, we gathered a significantly higher number of reports, with 148 for RRP, 243 for LRP, and 282 for RARP. The increase in the number of reports generated by our approach yielded worse results than those reported by Tewari et al, with overall rates of perioperative complications of 20.2%, 16.3%, and 12.3% for RRP, LRP, and RARP, with significant differences for all three pairwise comparisons (Table 2).
Table 3 – Descriptive statistics for perioperative variables by surgical technique and univariate comparative analysis of mean values stratified into four periods according to the year of publication of the studies

| Parameter                      | 1st period (before 2005) | 2nd period (2006–2010) | 3rd period (2011–2015) | 4th period (after 2015) |
|--------------------------------|--------------------------|------------------------|------------------------|-------------------------|
|                                | Variable mean (N; SE)    | p value                | Variable mean (N; SE)  | p value                 |
|                                | A: RRP       B: LRP      C: RARP |                       | A: RRP       B: LRP      C: RARP |                       |
| Age (yr)                       | 62.7 (115; 0.3)          | 62.6 (89; 0.3)         | 60.3 (35; 0.5)         | 0.001                   |
|                               | 62.3 (246; 0.2)          | 62.35 (166; 0.2)       | 60.59 (337; 0.1)       | 0.001                   |
| BMI (kg/m²)                    | 25.4 (3; 1.6)            | 26.8 (31; 0.3)         | 27.4 (36; 0.2)         | 0.144                   |
|                               | 26.57 (75; 0.2)          | 26.46 (65; 0.2)        | 27.39 (232; 0.1)       | 0.001                   |
| iPSA (mg/dl)                   | 9.2 (80; 0.5)            | 8.8 (87; 0.3)          | 7.7 (36; 0.3)          | 0.039                   |
|                               | 8.94 (202; 0.4)          | 8.61 (157; 0.2)        | 7.02 (298; 0.2)        | 0.002                   |
| iPSA <4 mg/dl (%)              | 17.3 (62; 23)            | 12.2 (23; 1.9)         | 0.28 (23; 1.9)         | 0.640                   |
|                               | 18.57 (14; 2.3)          | 20.20 (14; 5.6)        | 21.70 (29; 1.2)        | 0.048                   |
| iPSA 4–10 mg/dl (%)            | 56.1 (26; 1.8)           | 58.5 (26; 6.2)         | 0.546 (23; 2.5)        | 0.036                   |
|                               | 59.31 (23.5; 18; 3.5)    | 61.04 (29; 1.2)        | 66.68 (3; 1.2)         | 0.048                   |
| iPSA 10–20 mg/dl (%)           | 20.6 (24; 1.3)           | 26.3 (7; 3.2)          | 0.063 (14; 2.1)        | 0.005                   |
|                               | 18.96 (17; 2.7)          | 21.57 (12; 1.1)        | 10.43 (12; 1.1)        | 0.000                   |
| iPSA >20 mg/dl (%)             | 8.2 (16; 1.1)            | 33.0 (20; 3.0)         | 0.011 (8; 2.5)         | 0.030                   |
|                               | 9.33 (7.39)              | 7.18 (6; 0.2)          | 12.8 (6; 0.2)          | 0.083                   |
| cGS (mean)                     | 5.8 (25; 0.1)            | 6.0 (50; 0.1)          | 6.4 (12; 0.2)          | 0.001                   |
|                               | 6.17 (49; 0.1)           | 6.25 (76; 0.1)         | 6.36 (85; 0.1)         | 0.036                   |
| cGS >7 (%)                     | 68.8 (33; 1.7)           | 46.9 (<0.001)          | 56.87 (104; 2.0)       | 0.136                   |
|                               | 59.17 (48; 2.1)          | 62.9 (169; 3.3)        | 60.54 (169; 3.3)       | 0.036                   |
| cGS 7 (%)                      | 24.9 (29; 1.2)           | 35.2 (<0.001)          | 34.14 (96; 1.1)        | 0.126                   |
|                               | 34.14 (47; 1.5)          | 30.48 (159; 0.9)       | 31.05 (159; 0.9)       | 0.126                   |
| cGS >7 (%)                     | 6.1 (33; 0.9)            | 4.2 (10; 0.2)          | 0.006 (92; 1.1)        | 0.126                   |
|                               | 10.47 (11; 0.2)          | 8.37 (51; 0.1)         | 9.65 (51; 0.1)         | 0.126                   |
| Stage cT1 (%)                  | 50.6 (64; 2.7)           | 56.2 (57; 3.1)         | 0.235 (122; 1.7)       | 0.000                   |
|                               | 61.96 (88; 2.4)          | 58.91 (187; 1.0)       | 74.36 (126; 1.9)       | 0.000                   |
| Stage cT1a (%)                 | 2.3 (14; 0.3)            | 1.5 (11; 0.3)          | 0.059 (11; 2.3)        | 0.003                   |
|                               | 3.33 (12; 3.5)           | 3.13 (10; 0.6)         | 1.09 (10; 0.6)         | 0.003                   |
| Stage cT1b (%)                 | 4.8 (16; 0.8)            | 0.5 (12; 3.1)          | 0.001 (11; 2.2)        | 0.001                   |
|                               | 9.37 (11; 1.6)           | 7.07 (13; 4.3)         | 0.71 (12; 0.2)         | 0.001                   |
| Stage cT1c (%)                 | 52.6 (46; 3.5)           | 57.7 (40; 3.5)         | 0.490 (18; 4.8)        | 0.001                   |
|                               | 61.69 (26; 7.7)          | 58.93 (122; 2.2)       | 74.64 (122; 2.2)       | 0.001                   |
| Stage cT2 (%)                  | 47.1 (64; 2.5)           | 39.4 (55; 2.4)         | 0.082 (115; 16)        | 0.001                   |
|                               | 34.41 (88; 2.1)          | 40.99 (166; 1.3)       | 26.67 (166; 1.3)       | 0.001                   |
| Stage cT2a (%)                 | 27.6 (33; 1.9)           | 26.4 (19; 3.8)         | 0.836 (19; 3.8)        | 0.001                   |
|                               | 25.48 (41; 1.9)          | 25.22 (45; 1.5)        | 19.43 (81; 0.9)        | 0.001                   |
| Stage cT2b (%)                 | 20.6 (30; 2.8)           | 11.1 (35; 1.9)         | 0.029 (32; 1.6)        | 0.001                   |
|                               | 11.75 (40; 1.5)          | 9.40 (59; 0.7)         | 5.72 (59; 0.7)         | 0.001                   |
| Stage cT2c (%)                 | 7.7 (2.3)                | 2.3 (1.0)              | 0.028 (11.15; 0.4)     | 0.001                   |
|                               | 11.15 (40; 1.5)          | 8.61 (59; 0.7)         | 4.98 (59; 0.7)         | 0.001                   |
| Parameter | 1st period (before 2005) | 2nd period (2006–2010) | 3rd period (2011–2015) | 4th period (after 2015) |
|-----------|--------------------------|------------------------|------------------------|------------------------|
|           | Variable mean (N; SE)    | p value                | Variable mean (N; SE)  | p value                |
|           | A: RRP B: LRP C: RARP   |                        | A: RRP B: LRP C: RARP  |                        |
| Parameter | (17; 1.5) (8; 0.9) (3; 1.1) | BC<sup>a</sup>         | (19; 2.3) (36; 1.5) (24; 0.9) | N.S.                    |
| Stage cT3 (%) | 3.0 (36; 0.5) (21; 2.7) (10; 2.8) | BC<sup>c</sup>         | (6; 21.1) (38; 1.1) (71; 0.6) | AC/BC<sup>c</sup>       |
| Stage cT3a (%) | 2.4 (9; 0.7) (10; 2.7) (7; 3.5) | AB<sup>b</sup>         | (8; 12.3) (23; 21) (13; 2.2) | AC<sup>c</sup>          |
| Stage cT3b (%) | 0.0 (5; 0.0) (11.2; 3.5) (4; 1.1) | N.A.                  | (3; 3.0) (11; 0.9) (12; 1.1) | N.S.                    |
| Stage cT4 (%) | 0.0 (1; N.A.) (11.2; 3.5) (4; 1.1) | N.A.                  | (2.38 (4; 1.2) (N.A.) | 0.854                   |
| Operative time (min) | 186.6 (25; 8.6) (81; 8.4) (35; 20.6) | AB<sup>c</sup>         | (115; 4.3) (138; 4.9) (248; 3.8) | AC/AB<sup>c</sup>       |
| EBL (ml) | 1 091.3 (30; 77.2) (54; 34.0) (34; 43.3) | AC/BC<sup>b</sup>     | 868.88 (130; 34.8) (124; 19.0) (246; 8.0) | <0.001 |
| BT rate (%) | 21.0 (26; 3.8) (66; 1.1) (24; 1.7) | AB/AC<sup>c</sup>     | 21.84 (96; 2.1) (97; 0.9) (129; 0.4) | AC/AB<sup>c</sup>       |
| LOS (d) | 6.4 (28; 0.8) (46; 0.4) (27; 0.6) | AC/BC<sup>c</sup>     | 6.27 (88; 0.5) (99; 0.4) (172; 0.2) | AC/AB<sup>c</sup>       |
| Catheter time (d) | 12.0 (24; 3.0) (60; 0.3) (27; 0.8) | AB/AC<sup>c</sup>     | 11.12 (46; 0.7) (86; 0.3) (117; 0.2) | AC/AB<sup>c</sup>       |
| Complication rate (%) | 20.3 (50; 2.3) (71; 1.6) (24; 1.6) | AC/BC<sup>c</sup>     | 17.28 (63; 1.8) (101; 1.2) (126; 0.8) | AC<sup>c</sup>          |

**RRP** = open radical prostatectomy; **LRP** = laparoscopic radical prostatectomy; **RARP** = robot-assisted radical prostatectomy; **N** = number of reports; **SE** = standard error of the mean; **N.S.** = not significant (two-tailed p > 0.05); 
**N.A.** = not applicable; **BMI** = body mass index; **IPSA** = initial prostate-specific antigen; **cGS** = clinical Gleason score; **EBL** = estimated blood loss; **BT** = blood transfusion; **LOS** = length of stay

<sup>1</sup> p value for analysis of variance with multiple comparison tests among groups A (RRP), B (LRP), and C (RARP) with appropriate correction: a, Tukey; b, Bonferroni; or c, Games-Howell correction.
| Parameter                              | A: RRP | B: LRP | C: RARP | Significant correlation with complication rate* |
|----------------------------------------|--------|--------|---------|-----------------------------------------------|
| AVSS                                   |        |        |         |                                               |
| r                                      | -0.274 | -0.233 | -0.141  |                                               |
| p value                                | 0.023  | 0.003  | 0.043   |                                               |
| N₀                                    | 69     | 160    | 206     |                                               |
| Age (yr)                               |        |        |         |                                               |
| r                                      | 0.332  | 0.126  | 0.056   |                                               |
| p value                                | <0.001 | 0.056  | 0.363   |                                               |
| N₀                                    | 109    | 229    | 268     |                                               |
| Body mass index (kg/m²)                |        |        |         |                                               |
| r                                      | -0.025 | 0.079  | 0.086   |                                               |
| p value                                | 0.881  | 0.401  | 0.217   |                                               |
| N₀                                    | 84     | 220    | 247     |                                               |
| PSA (mg/dl)                            |        |        |         |                                               |
| r                                      | -0.224 | -0.006 | 0.032   |                                               |
| p value                                | 0.461  | 0.98   | 0.896   |                                               |
| N₀                                    | 13     | 17     | 19      |                                               |
| PSA <4 mg/dl (%)                       |        |        |         |                                               |
| r                                      | 0.332  | 0.126  | 0.056   |                                               |
| p value                                | <0.001 | 0.056  | 0.363   |                                               |
| N₀                                    | 109    | 229    | 268     |                                               |
| PSA 4–10 mg/dl (%)                     |        |        |         |                                               |
| r                                      | -0.534 | 0.312  | -0.034  |                                               |
| p value                                | 0.049  | 0.147  | 0.889   |                                               |
| N₀                                    | 14     | 23     | 19      |                                               |
| PSA 10–20 mg/dl (%)                    |        |        |         |                                               |
| r                                      | 0.417  | -0.276 | -0.264  |                                               |
| p value                                | 0.178  | 0.181  | 0.613   |                                               |
| N₀                                    | 12     | 25     | 6       |                                               |
| PSA >20 mg/dl (%)                      |        |        |         |                                               |
| r                                      | -0.639 | -0.272 | N.A.    |                                               |
| p value                                | 0.246  | 0.392  | N.A.    |                                               |
| N₀                                    | 5      | 12     | 1       |                                               |
| Clinical GS (mean)                     |        |        |         |                                               |
| r                                      | -0.125 | -0.001 | -0.305* |                                               |
| p value                                | 0.533  | 0.993  | 0.011   |                                               |
| N₀                                    | 27     | 105    | 68      |                                               |
| Clinical GS <7 (%)                     |        |        |         |                                               |
| r                                      | -0.051 | -0.194 | 0.013   |                                               |
| p value                                | 0.745  | 0.068  | 0.873   |                                               |
| N₀                                    | 43     | 89     | 150     |                                               |
| Clinical GS 7 (%)                      |        |        |         |                                               |
| r                                      | -0.074 | 0.234* | 0.051   |                                               |
| p value                                | 0.651  | 0.034  | 0.543   |                                               |
| N₀                                    | 40     | 83     | 144     |                                               |
| Stage cT1 (%)                          |        |        |         |                                               |
| r                                      | -0.300*| 0.129  | 0.003   |                                               |
| p value                                | 0.018  | 0.146  | 0.967   |                                               |
| N₀                                    | 62     | 129    | 145     |                                               |
| Stage cT1a (%)                         |        |        |         |                                               |
| r                                      | -0.217 | -0.25  | 0.276   |                                               |
| p value                                | 0.547  | 0.317  | 0.44    |                                               |
| N₀                                    | 10     | 18     | 10      |                                               |
| Stage cT1b (%)                         |        |        |         |                                               |
| r                                      | -0.178 | 0.129  | 0.178   |                                               |
| p value                                | 0.581  | 0.547  | 0.58    |                                               |
| N₀                                    | 12     | 24     | 12      |                                               |
| Stage cT1c (%)                         |        |        |         |                                               |
| r                                      | -0.384*| 0.135  | -0.087  |                                               |
| p value                                | 0.009  | 0.207  | 0.398   |                                               |
| N₀                                    | 45     | 89     | 97      |                                               |
| Stage cT2 (%)                          |        |        |         |                                               |
| r                                      | 0.295* | -0.147 | 0.019   |                                               |
| p value                                | 0.023  | 0.103  | 0.831   |                                               |
| N₀                                    | 59     | 125    | 135     |                                               |
| Stage cT2a (%)                         |        |        |         |                                               |
| r                                      | -0.159 | -0.143 | 0.076   |                                               |
| p value                                | 0.457  | 0.253  | 0.537   |                                               |
| N₀                                    | 24     | 66     | 68      |                                               |
| Stage cT2b (%)                         |        |        |         |                                               |
| r                                      | 0.007  | -0.056 | -0.211  |                                               |
| p value                                | 0.975  | 0.662  | 0.1     |                                               |
| N₀                                    | 21     | 63     | 62      |                                               |
| Stage cT2c (%)                         |        |        |         |                                               |
| r                                      | 0.411  | -0.006 | 0.061   |                                               |
| p value                                | 0.145  | 0.971  | 0.719   |                                               |
| N₀                                    | 14     | 43     | 37      |                                               |
| Stage cT3 (%)                          |        |        |         |                                               |
| r                                      | -0.034 | -0.114 | -0.194  |                                               |
| p value                                | 0.857  | 0.342  | 0.097   |                                               |
| N₀                                    | 30     | 71     | 74      |                                               |
| Stage cT3a (%)                         |        |        |         |                                               |
| r                                      | -0.021 | -0.169 | 0.216   |                                               |
| p value                                | 0.953  | 0.354  | 0.346   |                                               |
| N₀                                    | 10     | 32     | 21      |                                               |
| Stage cT3b (%)                         |        |        |         |                                               |
| r                                      | 0.806  | 0.149  | -0.496  |                                               |
| p value                                | 0.403  | 0.568  | 0.085   |                                               |
| N₀                                    | 3      | 17     | 13      |                                               |
| Stage cT4 (%)                          |        |        |         |                                               |
| r                                      | 0.25   | -1.000*| 0.528   |                                               |
| p value                                | 0.685  | -0.001 | 0.224   |                                               |
| N₀                                    | 5      | 2      | 7       |                                               |

RRP = open radical prostatectomy; LRP = laparoscopic radical prostatectomy; RARP = robot-assisted radical prostatectomy; r = correlation coefficient; N₀ = number of reports; N.S. = not significant; N.A. = not applicable; AVSS = annual volume of surgeries per surgeon; PSA = prostate-specific antigen; GS = Gleason score.

* Significant (two-tailed \( p < 0.05 \)).
Temporal analysis over the four periods showed that in the first 5 yr after the emergence of minimally invasive surgery, RARP was not used for simpler and low-risk cases, since these patients were more frequent in LRP and RRP study cohorts (Table 3). At this stage, perioperative results with robotic surgery were not very different from those with the other techniques. In the second period, more studies involving patients with low risk undergoing RARP were published, with a consistent improvement in results up to the fourth period. In an analysis of publications carried out by our group [11], we found that the peak for publications on robotic surgery occurred in 2010, between the second and third periods (2005–2015), demonstrating the effort of the scientific community to consolidate RARP as the gold standard [12].

Comparison of the data from our methodology with prior knowledge from the literature reveals that RSR generated worse results for all outcomes, which probably reflects one of the main characteristics of this method. The fact that simple SRs show better results may be because of the need to apply strict criteria for inclusion of studies in the analyses. When several studies are included and a heterogeneous sample of population character is generated, the central limit theorem instantly increases in strength and generates a narrow standard error of the mean, increasing the precision of the population mean, which is then more representative of the real world. Many readers accustomed to the methodological and Cartesian rigor of classical SRs may see this effect as a selection bias; however, other readers who live in a practical real-life world may identify more with RSR results, since these encompass several scenarios that can be extrapolated to daily practice, and the precision and homogeneity of classic SR can be seen as a bias in the same sense.

Our study revealed interesting data regarding the annual volume of surgeries that a surgeon needs to perform to obtain a complication rate similar to the average rate for RARP. To achieve a mean rate of 12.3% for overall complications, a surgeon needs to perform 95 surgeries/yr for RRP and LRP, in contrast to 30 surgeries/yr for RARP. This finding can be interpreted in two ways. A first, more superficial interpretation leads to the conclusion that the RARP learning curve is shorter, as the best complication rate among the three techniques is achieved with a lower frequency of surgeries (average of 2.5 surgeries/mo). However, a second, more in-depth analysis may identify an important selection bias in RARP studies. Considering that the average volume of annual surgeries for RARP is 64, compared to 43 for RRP and 41 for LRP, it is evident that RARP procedures are carried out by surgeons who perform a greater volume of surgeries and are therefore more experienced. In addition, studies on RARP included patients with lower-risk disease, with a higher proportion of patients with PSA <10 mg/dl, Gleason <7, and stage <cT2 (Table 1); in addition, this cohort had a lower rate of lymphadenectomy, which adds complications in the postoperative period. Corroborating this expectation, there was a higher rate of neurovascular bundle preservation for RARP, which is usually performed in patients with lower oncological risk.

In a population study performed before the minimally invasive era, Hu et al [13] analyzed the rates of in-hospital complications for 2292 patients undergoing RRP between 1997 and 1998 in 1210 hospitals using Medicare data. The authors found a complication rate of 21.9% for low-volume (<40 surgeries/yr) and 11.8% for high-volume surgeons (≥40 surgeries/yr), with the latter similar to the rates described for RARP in our study.

| Analysis | Surgical approach | RRP | LRP | RARP |
|---|---|---|---|---|
| Simple correlation | Pearson correlation coefficient | –0.274 | –0.233 | –0.141 |
| | p value | 0.023 | 0.003 | 0.043 |
| Curve fit in the rational model | Coefficient of determination (r²) | 0.67 | 0.35 | 0.43 |
| | Coefficient of determination (r²) | 0.45 | 0.12 | 0.19 |
| Complication rate (%) | | 12.3 | 12.8 | 12.3 |
| Annual surgery volume per surgeon | | 95.33 | 95.41 | 30.15 |

RRP = open radical prostatectomy; LRP = laparoscopic radical prostatectomy; RARP = robot-assisted radical prostatectomy.

Fig. 3 – Nonlinear regression models for correlation of complication rates and annual surgery volume per surgeon for each technique. Red lines denote nonlinear regression based on the rational model. RRP = open radical prostatectomy; LRP = laparoscopic radical prostatectomy; RARP = robot-assisted radical prostatectomy.
The main limitation of our study is inherent to the methodology itself. The fact that the RSR includes all the studies from the SRs, regardless of the inclusion criteria, means that the sample is composed of studies that differ in quality and design. This generates a sample space with as many biases as possible until a population sample that is representative of different clinical scenarios is reached. However, this limitation is purposeful in order to allow readers to understand the power of the population sample and bring the literature data closer to “real-world” findings, since the considerable increase in sample size increases the precision of the population mean according to the central limit theorem. If readers need to compare studies in a homogeneous way, there is already an established methodology that is powerful enough to give such answers—the classic SR with meta-analysis—but with scenarios that are often unrepresentative of the reality in practice for many urologists. The intent of our methodology is not to provide a contrast to data from classic SRs but rather to provide a view of the literature data from a different perspective. If urologists need specific answers, they will certainly find more precise information from SRs with meta-analysis. However, if there is a need for a broader and more representative perspective, the data from this study can be used for comparison of results, including a surgeon’s own results.

Another limitation is related to the presence of weak correlations in the univariate analysis ($r < 0.39$), which indicates that other variables have an influence on the complication rates. This is a consequence of the heterogeneous sample, which is a potential point of criticism. However, because of the high degree of independence and the population nature of the sample, finding a significant correlation, even if weak, made it possible to perform an adjustment in the nonlinear regression with improved correlation and, mainly, with an established clinical logic.

In addition, the narrow standard error of the mean, generated by the population sample over a period of more than 20 yr, makes it statistically practically impossible to change these results, allowing the generation of new reference values to guide patients in the choice between RP techniques.

5. Conclusions

Our RSR, which included a wide real-life representative sample and reference values established in the literature, revealed that minimally invasive surgery had the best perioperative and complication results, especially RARP, which was associated with less complex cases, higher annual surgeon volume, and greater performance. To achieve the same levels of complications as with RARP, the annual volume of surgery would need to be three times greater for RRP and LRP, which demonstrates the greater expertise of robotic surgeons compared to surgeons performing the other techniques in the SRs.

Our study can be used as a tool to guide patients and physicians in deciding on the best surgical treatment according to availability. Future studies using the database we constructed for this study could provide information on other oncological and functional outcomes.
[8] Dindo D, Demartines N, Clavien PA. Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey. Ann Surg 2004;240:205–13.

[9] Novara G, Ficarra V, Rosen RC, et al. Systematic review and meta-analysis of perioperative outcomes and complications after robot-assisted radical prostatectomy. Eur Urol 2012;62:431–52.

[10] Tewari A, Sooriakumaran P, Bloch DA, Seshadri-Kreaden U, Hebert AE, Wiklund P. Positive surgical margin and perioperative complication rates of primary surgical treatments for prostate cancer: a systematic review and meta-analysis comparing retropubic, laparoscopic, and robotic prostatectomy. Eur Urol 2012;62:1–15.

[11] Moretti TBC, Reis LO. The “natural history” of evidence on radical prostatectomy: what have 20 years of robots given us? Eur Urol Focus. In press. https://doi.org/10.1016/j.euf.2022.06.006.

[12] Cacciamani G, Desai M, Siemens DR, Gill IS. Robotic urologic oncologic surgery: ever-widening horizons. J Urol 2022;208:8–9.

[13] Hu JC, Gold KF, Pashos CL, Mehta SS, Litwin MS. Role of surgeon volume in radical prostatectomy outcomes. J Clin Oncol 2003;21:401–5.